Suppression of DNMT1 combined with ATM or ATR inhibitor as a therapeutic combination of acute myeloid leukemia
Lei Liu,Xiaoyan Hu,Jing Feng,Anhui Lei,Shiying Huang,Xian Liu,Hui Liu,Lan Luo,Wenyan Yao
DOI: https://doi.org/10.1097/cad.0000000000001564
2024-02-29
Anti-Cancer Drugs
Abstract:Acute myeloid leukemia (AML) is a common type of adult leukemia, and its incidence increases with age, with a poor overall prognosis [ 1 ]. The incidence of AML in the USA is approximately 4.3/100 000, with a 5-year survival rate of about 24% [ 1 ]. Most AML patients experience relapse within 12 months after treatment, but the risk of relapse decreases over time [ 2 ]. According to the European LeukemiaNet (ELN) scoring system for prognosis evaluation of relapsed young AML patients (age ≤ 60), the proportion of high-risk relapsed AML patients is 66%, with 1-year and 5-year overall survival rates of 16% and 4% respectively [ 3 ]. ELN confirmed that shorter time to relapse, adverse genetic characteristics, and older age at relapse are positively correlated with poor prognosis. With current treatment methods, the complete remission rate (CR) of AML can reach 50–80%, but more than 20% of AML patients still cannot achieve CR. Furthermore, most AML patients who achieve CR will still experience relapse, leading to clinically relapsed/refractory AML [ 4 ]. In AML patients who are not suitable for intensive chemotherapy, hypomethylating agents (azacitidine and decitabine) alone or in combination with FLT3 inhibitors, IDH1/2 inhibitors, or BCL2 inhibitors are used as standard treatment regimens [ 2 ]. At present, targeted therapy combined with hypomethylating agents remains the main treatment approach in relapsed/refractory AML patients [ 5 ]. DNA methyltransferase 1 (DNMT1) is a member of the DNMT family, unlike DNMT3A and DNMT3B, which de novo synthesize DNA methylation patterns, DNMT1 is responsible for introducing methylation into the daughter strand after DNA replication [ 6 ]. Members of the DNMT family are closely associated with the progression of AML, and inhibiting the function of DNMT1 significantly reduces the methylation level of the daughter strand, thereby inhibiting the malignant phenotype of AML [ 6 ]. In AML cell and animal models, the robust loss of DNA methylation, transcriptional activation, and inhibition of cancer cell growth are induced by a reversible DNMT1-selective inhibitor that competes with the active-site loop of DNMT1 to penetrate hemi-methylated DNA between two CpG base pairs [ 7 ]. In addition, DNMT1 could be a potential synthetic lethal target in AML cases with DNMT3A mutation [ 8 ].
oncology,pharmacology & pharmacy